CN109406795A

CN109406795A - A kind of serum molecules diagnostic marker of light-duty brain trauma and application

Info

Publication number: CN109406795A
Application number: CN201811387271.1A
Authority: CN
Inventors: 王廷华; 牛瑞泽; 刘佳; 鲍天昊
Original assignee: Kunming Medical University
Current assignee: Kunming Medical University
Priority date: 2018-11-20
Filing date: 2018-11-20
Publication date: 2019-03-01

Abstract

The invention discloses a serum molecular diagnostic marker for mild brain trauma and its application. The marker comprises one or more of NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9 or ICAM-2. several. Its amino acid sequence is shown as SEQ ID NO.1-SEQ ID NO.8. The above markers can be used in the preparation of light traumatic brain injury diagnostic products. The invention provides a non-invasive method for clinical early diagnosis of mild brain trauma, and is suitable for clinical promotion.

Description

A kind of serum molecules diagnostic marker of light-duty brain trauma and application

Technical field

The invention belongs to genes and field of biotechnology, specifically, the serum molecules for being related to a kind of light-duty brain trauma are examined Disconnected marker and application.

Background technique

Brain trauma refers to as caused by foreign object, the macroscopic wound in brains portion, can generally cause serious consequence.Not same district The cerebral lesion in domain can cause different symptoms, and focal symptom includes the symptoms such as movement, feeling, speech, vision, abnormal auditory perception. And diffuse brain damage often influences to remember, sleep or cause clouding of consciousness and stupor.With the development of modern industry and traffic, cranium The incidence of cerebral trauma is high, becomes and threatens the mankind, and special Young crowd life is main sick and wounded with health.According to beauty The report of state's Disease Control and Prevention Center, about 1,700,000 Americans meet with craniocerebral trauma every year, and wherein 75%-90% is light Type traumatic brain injury.

Although there have injured process, whole body and nervous system physical examination to find that various performances can clarify a diagnosis according to patient to be middle heavy Brain trauma is spent, but light-duty brain trauma is due to acute symptom, such as memorys loss, disorientation etc. after the loss of consciousness, wound in short-term, through not Alleviate rapidly after breath, and lack the objective evidence of damage on neuroimaging, therefore, it is difficult to clarify a diagnosis.

Currently, the diagnosis basis of light-duty brain trauma is: Glasgow coma score (GCS) 13-15 divides, goes into a coma less than 20 points Clock.However patient goes into a coma, history cannot obtain sometimes, such as infant, the old man of dysnoesia, multiple trauma；Or stupor history can not It leans on, such as drunk, recreational drug, sedative；Or patient reports stupor history unbearably intentionally.For clearly light-duty brain trauma diagnosis and effectively Prognosis prediction, need a kind of practical and objective method.

Studies have shown that some serum biomarkers can provide valuable reference to the diagnosis of light-duty brain trauma, biology Marker may be the useful auxiliary examination index that light-duty brain trauma is clarified a diagnosis, and be clinical examination and neuroimaging inspection Valuable supplement.For patients with cerebral injury, using new biomarker, it is quick, authoritative, noninvasive, accurate to provide Experimental index, guidance point examines, predict prognosis, promoting the further improvement treated, provide possibility for early treatment intervention.It is raw Object marker is specific objective indicator in physiology or pathologic process, can by body fluid, such as cerebrospinal fluid and blood measuring, TBI's Biomarker refers to that TBI causes brain cell injury to destroy, disintegrate, neuron or Deiter's cells discharge specific proteins into Enter body fluid (cerebrospinal fluid and blood), the severity of the horizontal pathophysiological mechanism caused to wound and damage is related.

The biomarker of brain trauma, the determination of especially light-duty brain trauma biomarker, is faced with some challenges, newly Biomarker as a kind of useful clinical auxiliary examination, should have following 3 basic characteristics: first, the brain of height is special Quickly occur in body fluid after the opposite sex, accuracy and wound；Second, analysis method is reliable and repeatable measurement, reasonable cost and compared with Short detection time, and the high sensitivity of detection；Third can provide diagnosis and prognosis information, facilitate the sight of clinician It examines, treat and prognosis prediction.

Protein science research is an one of general orientation for the life science development after i.e. genomics research.Protein Structure and function finally directly affects the variation of vital movement, and the research of gene transcription level can only reflect to a certain extent The variation of gene expression product, and the albumen really functioned will add after transcription post-processing, translational control and translation Many steps such as work and regulation could be formed, thus could really explain various biological phenomenas to directly researching for protein. But study protein means and method not yet very big development, so find effectively, efficiently protein analytical techniques at For a vital link.The appearance of protein chip technology brings new approaches to protein science research.Protein science is ground Study carefully the quantitative change that a main content seeks to study the protein level under different physiological status or pathological state, be miniaturized, Integrated, the antibody chip of high pass quantization is exactly an extraordinary research tool, it is also with fastest developing speed in protein chip Chip, and it is technically increasingly mature.These antibody chip some are developing in clinical application, such as tumour Marker antibody chip etc., there are also much have been used in the every field of research.

Enzyme immunoassay (EIA) be the specificity of the high efficiency of enzyme catalysis and antigen-antibody reaction is combined one kind it is micro- Measure analytical technology.The enzyme marker formed after enzyme-labelled antigen or antibody had not only retained the immunocompetence of antigen or antibody, but also had retained The catalytic activity of enzyme.When enzyme marker interacts with corresponding antigen in sample to be measured or antibody.It is anti-that enzyme label can be formed Original antibody compound.It is developed the color using the substrate for enzymatic activity marked on compound, antigen is anti-in the depth of color and sample to be checked The amount of body is related.This method susceptibility can reach ng/ml~pg/ml level.

Enzyme-linked immunosorbent assay (ELISA) is technology most widely used in enzyme immunoassay (EIA), be can be used for qualitative or quantitative Detect antigen.

Summary of the invention

In view of this, the present invention provides a kind of serum molecules diagnostic marker of light-duty brain trauma and applications, it is intended to solve Certainly clinical light-duty brain trauma lacks effective diagnosis and method for prediction of prognosis.

In order to solve the above-mentioned technical problem, the invention discloses a kind of serum molecules diagnostic marker of light-duty brain trauma, Including one or more of NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9 or ICAM-2.

Optionally, the amino acid sequence of NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9 and ICAM-2 such as SEQ ID Shown in NO.1-SEQ ID NO.8.

The invention also discloses a kind of serum molecules diagnostic markers of above-mentioned light-duty brain trauma to prepare outside light-duty brain Hurt the application in diagnostic products.

Optionally, the diagnostic products include the reagent for detecting one or more markers, and the reagent passes through inspection The concentration of one or more markers described in experimenter's serum is surveyed to judge whether subject suffers from light-duty brain trauma.

Optionally, the reagent is when detecting one or more marker concentrations based on genechip detection or PCR Required reagent.

Optionally, one of described marker NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9, ICAM-2 or several Kind expression in light-duty brain trauma tissue is significantly increased compared with expressing in non-light-duty brain trauma tissue.

Optionally, the diagnostic products are kit, chip or detection platform.

The invention also discloses a kind of light-duty brain trauma diagnostic kit, the kit is for detecting in light-duty brain trauma One or more of NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9, ICAM-2.

Optionally, which includes eight kinds of albumen of NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9 and ICAM-2 Specific antibody.

Include solid phase carrier the invention also discloses a kind of light-duty brain trauma protein chip for diagnosing and is fixed on solid phase The specific antibody of eight kinds of albumen of NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9 and ICAM-2 of carrier.

Compared with prior art, the present invention can be obtained including following technical effect:

1) protein expression profiles in TBI patients serum are determined, find NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP- 9 and ICAM-2 differential expression is significant；And application ELISA test further demonstrates above-mentioned discovery.

2) the present invention provides effective disease blood serum mark object detecting method, and find NGF, NT-3, IGF-2, HGF, The molecular diagnosis system of eight kinds of albumen such as NPY, CRP, MMP-9 and ICAM-2 composition can be used as the serum of patients with minimal head injury Diagnostic marker.

Certainly, it implements any of the products of the present invention it is not absolutely required to while reaching all the above technical effect.

Detailed description of the invention

The drawings described herein are used to provide a further understanding of the present invention, constitutes a part of the invention, this hair Bright illustrative embodiments and their description are used to explain the present invention, and are not constituted improper limitations of the present invention.In the accompanying drawings:

Fig. 1 is the differentially expressed protein thermal map that protein chip of the present invention detects；Wherein, a and b respectively represent differential expression The protein of different expressions, shares 107 in upregulated protein；

Fig. 2 is the differentially expressed protein thermal map that another histone chip of the present invention detects；Wherein, a and b respectively represent difference The protein of different expressions, shares 65 in different expression down-regulation protein；

Fig. 3 is that most significant top ten and table are raised in expression in differential expression protein that protein chip of the present invention detects Up to the most significant top ten of downward；Wherein, a represents expression and raises most significant top ten, is Follistatin-like respectively 1, beta-NGF, Lefty-A, MMP-20, EG-VEGF/PK1, Decorin, Pref-1, HAI-2, MCP-4/CCL13 and IL- 22；B represents expression and lowers most significant top ten, is I-309, SAA, Notch-1, S100A8/A9, D-Dimer, IL- respectively 31, NT-4, CRP, MMP-9 and SCG3；

Fig. 4 is differentially expressed protein GO analysis of the present invention；

Fig. 5 is bioinformatics (interactions between protein) analysis that the protein of downward is expressed in protein chip result of the present invention；

Fig. 6 is the bioinformatics (interactions between protein) that the protein of downward is expressed in another histone chip results of the present invention Analysis；

Fig. 7 is the bioinformatics (albumen of the protein of all differences expression in another histone chip results of the present invention Interaction) analysis；

Fig. 8 is KEGG path analysis of the present invention；Wherein, A represents the KEGG path analysis of upregulated protein；B, which is represented, lowers egg White KEGG path analysis；

Fig. 9 is ELISA testing result of the present invention；Wherein, A represents CRP, and B represents ICAM-2, C and represents MMP-9, D representative HGF, E, which represent IGF-2, F and represent NGF, G, represents NT-3, and H represents NPY.

Specific embodiment

Carry out the embodiment that the present invention will be described in detail below in conjunction with embodiment, whereby to the present invention how application technology hand Section solves technical problem and reaches the realization process of technical effect to fully understand and implement.

The light-duty serum of patients with brain trauma diagnostic marker of embodiment 1

Light-duty serum of patients with brain trauma diagnostic marker include NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9 and Eight kinds of albumen of ICAM-2, amino acid sequence is respectively as shown in SEQ ID NO.1-SEQ ID NO.8.

1. experimental method

1. collect First Affiliated Hospital of Kunming Medical University receive TBI treatment 23 patients serums (19~81 years old, TBI The 3rd day as TBI group afterwards) and 22 healthy blood donors serum (18~81 years old, as a control group).

2. randomly selecting 3 TBI groups and 3 control group samples carrying out protein chip detection differentially expressed protein.

3. carrying out bioinformatic analysis to significant differentially expressed protein.

4. using ELISA test further demonstrate NGF, NT-3 in TBI patients serum, IGF-2, HGF, NPY, CRP, The raising of MMP-9 and ICAM-2 level.

2. experimental result

1. protein chip testing result shows that the significant albumen of differential expression has 172, wherein 107 protein expressions Up-regulation, 65 protein expressions lower (Fig. 1-Fig. 3).

2. differentially expressed protein GO analysis shows, the biological process of the albumen of these differential expressions is primarily involved in cell mistake Regulation, signal transduction, cell communication, the reaction to stimulation, the development (Fig. 4) of immune system process and multicellular organism of journey, As shown in figure 4, the protein of up-regulation takes part in 212 bioprocess, preceding 10 biological processes are single organism respectively Cell processes (38 kinds of protein), the signal (33 kinds of protein) of single organism, cell communication (33 kinds of protein), to stimulation Reaction (32 kinds of protein), multicellular organism develop (31 kinds of protein), signal transduction (31 kinds of protein), cell is to stimulation Reaction (31 kinds of protein), single multicellular organism process (30 protein), the adjusting (30 kinds of protein) of metabolic process, with And the positive adjusting (29 kinds of protein) (Fig. 4 A-a) of bioprocess.

In addition, the protein lowered takes part in 59 biological processes, preceding 10 biological processes are to biology respectively Positive adjustment process (23 kinds of protein), to the negative regulation (19 kinds of protein) of cell processes, the negative regulation (19 of biological process Kind protein), the adjusting (18 kinds of protein) of signal, cell communications adjust (18 kinds of protein), the positive regulation (18 of cell processes Kind protein), the adjusting (17 kinds of protein) of signal transduction stimulates (17 kinds of protein) to the adjusting of stimulate the reaction, siberian crabapple The positive regulator (16 kinds of protein) (Fig. 4 B-a) of system process (16 kinds of protein) and cellular process.

In the three types of this GO analysis, cell component is related with the activation of gene product.In this invention, we It was found that upregulated protein is mainly expressed in extracellular space and extracellular space part, in addition to this, further include extracellular space, Cytoplasma membrane bounded blister cavities, cell surface, serous coat part, secretory granules chamber and film surface (Fig. 4 A-b).Similarly, lower regulatory protein Cell component include extracellular space, extracellular space, extracellular space part, vesica film bounded vesicle, cytoplasma membrane has Boundary's cyst external capsule is extracellular, secretory granules, cytoplasm vesicle, cytoplasma membrane bounded vesicle, secretory granules chamber, cytoplasm vesicle part and interior At vesica chamber (Fig. 4 B-b).

Molecular function is characterized in the biochemical activity depending on a kind of gene product.The molecular function of upregulated protein matter is main It is to participate in receptor to combine, protein combines, cytokine activity, growth factor activity, chemotactic object activity, cell factor receptor Body combines, and chemokine receptor activity and BMP combine (Fig. 4 A-c), and the molecular function for expressing the protein lowered mainly is joined In conjunction with receptor, protein is combined, and lipoprotein particles combine and the combination (Fig. 4 B-c) of interleukin-6 receptor.

3. bioinformatics (interactions between protein) analysis shows, NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9 and There is more close functional cohesion (Fig. 5-Fig. 7) between ICAM-2.

As shown in figure 5, the PPI network for having obvious interaction relationship with upregulated protein includes 58 nodes and 82 sides. Wherein, first 5 pairs of optimum combination score are (0.991) nrg2-erbb3, ctnnb1-cdh5 (0.988), nrg2-erbb4 (0.984), ccl7-ccr2 (0.978) and ccl7-ccr1 (0.959).Value in bracket is combined fractional value.

As shown in fig. 6, there is the PPI network of obvious interaction relationship to include 51 nodes and 74 sides with down-regulation protein, Wherein, first 5 pairs of optimum combination score be GCG-GAST (0.99), EPO-KITLG (0.982), SMAD5-SMAD4 (0.968), GCG-VIPR2 (0.951) and IGF2-PAPPA (0.948).Value in bracket is combined fractional value.

As shown in fig. 7, the PPI network of all DEPs includes 109 nodes and 293 sides.Wherein, 5 pairs of highest scoring Combination be TF-TFRC (0.999), CCK-GAST (0.993), NGR2-ERBB3 (0.991), GCG-GAST (0.99) and CTNNB1-CDH5(0.988).Value in bracket is combined fractional value.

In addition, NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9 and ICAM-2 are in protein-protein interaction (PPI) also possess very high comprehensive score in network.

4. KEGG path analysis show the differentially expressed protein of up-regulation significant enrichment access be cell factor-cell because Sub- acceptor interaction access, PI3K-Akt signal path, oncoprotein polysaccharide access, RAPI signal path, RAS signal access With Jak-STAT signal path (Fig. 8 A).Meanwhile the enrichment access of the differentially expressed protein of downward have hematopoietic cell lineage and Notch signal path (Fig. 8 B).

5. ELISA testing result shows compared with the control group, TBI group CRP, ICAM-2, MMP-9, HGF, IGF-2, NGF, NT-3 and NPY obviously raises (P < 0.05) (Fig. 9).

Above description has shown and described several preferred embodiments of invention, but as previously described, it should be understood that invention is not It is confined to form disclosed herein, should not be regarded as an exclusion of other examples, and can be used for various other combinations, modification And environment, and can be carried out within that scope of the inventive concept describe herein by the above teachings or related fields of technology or knowledge Change.And changes and modifications made by those skilled in the art do not depart from the spirit and scope of invention, then it all should be in the appended power of invention In the protection scope that benefit requires.

SEQUENCE LISTING

<110>Kunming Medical University

<120>a kind of serum molecules diagnostic marker of light-duty brain trauma and application

<130> 2018

<160> 8

<170> PatentIn version 3.3

<210> 1

<211> 257

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 1

Met Ser Ile Leu Phe Tyr Val Ile Phe Leu Ala Tyr Leu Arg Gly Ile

1 5 10 15

Gln Gly Asn Asn Met Asp Gln Arg Ser Leu Pro Glu Asp Ser Leu Asn

20 25 30

Ser Leu Ile Ile Lys Leu Ile Gln Ala Asp Ile Leu Lys Asn Lys Leu

35 40 45

Ser Lys Gln Met Val Asp Val Lys Glu Asn Tyr Gln Ser Thr Leu Pro

50 55 60

Lys Ala Glu Ala Pro Arg Glu Pro Glu Arg Gly Gly Pro Ala Lys Ser

65 70 75 80

Ala Phe Gln Pro Val Ile Ala Met Asp Thr Glu Leu Leu Arg Gln Gln

85 90 95

Arg Arg Tyr Asn Ser Pro Arg Val Leu Leu Ser Asp Ser Thr Pro Leu

100 105 110

Glu Pro Pro Pro Leu Tyr Leu Met Glu Asp Tyr Val Gly Ser Pro Val

115 120 125

Val Ala Asn Arg Thr Ser Arg Arg Lys Arg Tyr Ala Glu His Lys Ser

130 135 140

His Arg Gly Glu Tyr Ser Val Cys Asp Ser Glu Ser Leu Trp Val Thr

145 150 155 160

Asp Lys Ser Ser Ala Ile Asp Ile Arg Gly His Gln Val Thr Val Leu

165 170 175

Gly Glu Ile Lys Thr Gly Asn Ser Pro Val Lys Gln Tyr Phe Tyr Glu

180 185 190

Thr Arg Cys Lys Glu Ala Arg Pro Val Lys Asn Gly Cys Arg Gly Ile

195 200 205

Asp Asp Lys His Trp Asn Ser Gln Cys Lys Thr Ser Gln Thr Tyr Val

210 215 220

Arg Ala Leu Thr Ser Glu Asn Asn Lys Leu Val Gly Trp Arg Trp Ile

225 230 235 240

Arg Ile Asp Thr Ser Cys Val Cys Ala Leu Ser Arg Lys Ile Gly Arg

245 250 255

Thr

<210> 2

<211> 257

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 2

Met Ser Ile Leu Phe Tyr Val Ile Phe Leu Ala Tyr Leu Arg Gly Ile

1 5 10 15

Gln Gly Asn Asn Met Asp Gln Arg Ser Leu Pro Glu Asp Ser Leu Asn

20 25 30

Ser Leu Ile Ile Lys Leu Ile Gln Ala Asp Ile Leu Lys Asn Lys Leu

35 40 45

Ser Lys Gln Met Val Asp Val Lys Glu Asn Tyr Gln Ser Thr Leu Pro

50 55 60

Lys Ala Glu Ala Pro Arg Glu Pro Glu Arg Gly Gly Pro Ala Lys Ser

65 70 75 80

Ala Phe Gln Pro Val Ile Ala Met Asp Thr Glu Leu Leu Arg Gln Gln

85 90 95

Arg Arg Tyr Asn Ser Pro Arg Val Leu Leu Ser Asp Ser Thr Pro Leu

100 105 110

Glu Pro Pro Pro Leu Tyr Leu Met Glu Asp Tyr Val Gly Ser Pro Val

115 120 125

Val Ala Asn Arg Thr Ser Arg Arg Lys Arg Tyr Ala Glu His Lys Ser

130 135 140

His Arg Gly Glu Tyr Ser Val Cys Asp Ser Glu Ser Leu Trp Val Thr

145 150 155 160

Asp Lys Ser Ser Ala Ile Asp Ile Arg Gly His Gln Val Thr Val Leu

165 170 175

Gly Glu Ile Lys Thr Gly Asn Ser Pro Val Lys Gln Tyr Phe Tyr Glu

180 185 190

Thr Arg Cys Lys Glu Ala Arg Pro Val Lys Asn Gly Cys Arg Gly Ile

195 200 205

Asp Asp Lys His Trp Asn Ser Gln Cys Lys Thr Ser Gln Thr Tyr Val

210 215 220

Arg Ala Leu Thr Ser Glu Asn Asn Lys Leu Val Gly Trp Arg Trp Ile

225 230 235 240

Arg Ile Asp Thr Ser Cys Val Cys Ala Leu Ser Arg Lys Ile Gly Arg

245 250 255

Thr

<210> 3

<211> 180

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 3

Met Gly Ile Pro Met Gly Lys Ser Met Leu Val Leu Leu Thr Phe Leu

1 5 10 15

Ala Phe Ala Ser Cys Cys Ile Ala Ala Tyr Arg Pro Ser Glu Thr Leu

20 25 30

Cys Gly Gly Glu Leu Val Asp Thr Leu Gln Phe Val Cys Gly Asp Arg

35 40 45

Gly Phe Tyr Phe Ser Arg Pro Ala Ser Arg Val Ser Arg Arg Ser Arg

50 55 60

Gly Ile Val Glu Glu Cys Cys Phe Arg Ser Cys Asp Leu Ala Leu Leu

65 70 75 80

Glu Thr Tyr Cys Ala Thr Pro Ala Lys Ser Glu Arg Asp Val Ser Thr

85 90 95

Pro Pro Thr Val Leu Pro Asp Asn Phe Pro Arg Tyr Pro Val Gly Lys

100 105 110

Phe Phe Gln Tyr Asp Thr Trp Lys Gln Ser Thr Gln Arg Leu Arg Arg

115 120 125

Gly Leu Pro Ala Leu Leu Arg Ala Arg Arg Gly His Val Leu Ala Lys

130 135 140

Glu Leu Glu Ala Phe Arg Glu Ala Lys Arg His Arg Pro Leu Ile Ala

145 150 155 160

Leu Pro Thr Gln Asp Pro Ala His Gly Gly Ala Pro Pro Glu Met Ala

165 170 175

Ser Asn Arg Lys

180

<210> 4

<211> 728

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 4

Met Trp Val Thr Lys Leu Leu Pro Ala Leu Leu Leu Gln His Val Leu

1 5 10 15

Leu His Leu Leu Leu Leu Pro Ile Ala Ile Pro Tyr Ala Glu Gly Gln

20 25 30

Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys Thr

35 40 45

Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys Val

50 55 60

Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly Leu

65 70 75 80

Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys Gln Cys

85 90 95

Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu Phe

100 105 110

Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn Cys

115 120 125

Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile Thr Lys

130 135 140

Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu His

145 150 155 160

Ser Phe Leu Pro Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr

165 170 175

Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr Ser

180 185 190

Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser Glu

195 200 205

Val Glu Cys Met Thr Cys Asn Gly Glu Ser Tyr Arg Gly Leu Met Asp

210 215 220

His Thr Glu Ser Gly Lys Ile Cys Gln Arg Trp Asp His Gln Thr Pro

225 230 235 240

His Arg His Lys Phe Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe Asp

245 250 255

Asp Asn Tyr Cys Arg Asn Pro Asp Gly Gln Pro Arg Pro Trp Cys Tyr

260 265 270

Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala Ile Lys Thr Cys

275 280 285

Ala Asp Asn Thr Met Asn Asp Thr Asp Val Pro Leu Glu Thr Thr Glu

290 295 300

Cys Ile Gln Gly Gln Gly Glu Gly Tyr Arg Gly Thr Val Asn Thr Ile

305 310 315 320

Trp Asn Gly Ile Pro Cys Gln Arg Trp Asp Ser Gln Tyr Pro His Glu

325 330 335

His Asp Met Thr Pro Glu Asn Phe Lys Cys Lys Asp Leu Arg Glu Asn

340 345 350

Tyr Cys Arg Asn Pro Asp Gly Ser Glu Ser Pro Trp Cys Phe Thr Thr

355 360 365

Asp Pro Asn Ile Arg Val Gly Tyr Cys Ser Gln Ile Pro Asn Cys Asp

370 375 380

Met Ser His Gly Gln Asp Cys Tyr Arg Gly Asn Gly Lys Asn Tyr Met

385 390 395 400

Gly Asn Leu Ser Gln Thr Arg Ser Gly Leu Thr Cys Ser Met Trp Asp

405 410 415

Lys Asn Met Glu Asp Leu His Arg His Ile Phe Trp Glu Pro Asp Ala

420 425 430

Ser Lys Leu Asn Glu Asn Tyr Cys Arg Asn Pro Asp Asp Asp Ala His

435 440 445

Gly Pro Trp Cys Tyr Thr Gly Asn Pro Leu Ile Pro Trp Asp Tyr Cys

450 455 460

Pro Ile Ser Arg Cys Glu Gly Asp Thr Thr Pro Thr Ile Val Asn Leu

465 470 475 480

Asp His Pro Val Ile Ser Cys Ala Lys Thr Lys Gln Leu Arg Val Val

485 490 495

Asn Gly Ile Pro Thr Arg Thr Asn Ile Gly Trp Met Val Ser Leu Arg

500 505 510

Tyr Arg Asn Lys His Ile Cys Gly Gly Ser Leu Ile Lys Glu Ser Trp

515 520 525

Val Leu Thr Ala Arg Gln Cys Phe Pro Ser Arg Asp Leu Lys Asp Tyr

530 535 540

Glu Ala Trp Leu Gly Ile His Asp Val His Gly Arg Gly Asp Glu Lys

545 550 555 560

Cys Lys Gln Val Leu Asn Val Ser Gln Leu Val Tyr Gly Pro Glu Gly

565 570 575

Ser Asp Leu Val Leu Met Lys Leu Ala Arg Pro Ala Val Leu Asp Asp

580 585 590

Phe Val Ser Thr Ile Asp Leu Pro Asn Tyr Gly Cys Thr Ile Pro Glu

595 600 605

Lys Thr Ser Cys Ser Val Tyr Gly Trp Gly Tyr Thr Gly Leu Ile Asn

610 615 620

Tyr Asp Gly Leu Leu Arg Val Ala His Leu Tyr Ile Met Gly Asn Glu

625 630 635 640

Lys Cys Ser Gln His His Arg Gly Lys Val Thr Leu Asn Glu Ser Glu

645 650 655

Ile Cys Ala Gly Ala Glu Lys Ile Gly Ser Gly Pro Cys Glu Gly Asp

660 665 670

Tyr Gly Gly Pro Leu Val Cys Glu Gln His Lys Met Arg Met Val Leu

675 680 685

Gly Val Ile Val Pro Gly Arg Gly Cys Ala Ile Pro Asn Arg Pro Gly

690 695 700

Ile Phe Val Arg Val Ala Tyr Tyr Ala Lys Trp Ile His Lys Ile Ile

705 710 715 720

Leu Thr Tyr Lys Val Pro Gln Ser

725

<210> 5

<211> 97

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 5

Met Leu Gly Asn Lys Arg Leu Gly Leu Ser Gly Leu Thr Leu Ala Leu

1 5 10 15

Ser Leu Leu Val Cys Leu Gly Ala Leu Ala Glu Ala Tyr Pro Ser Lys

20 25 30

Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp Met Ala Arg Tyr

35 40 45

Tyr Ser Ala Leu Arg His Tyr Ile Asn Leu Ile Thr Arg Gln Arg Tyr

50 55 60

Gly Lys Arg Ser Ser Pro Glu Thr Leu Ile Ser Asp Leu Leu Met Arg

65 70 75 80

Glu Ser Thr Glu Asn Val Pro Arg Thr Arg Leu Glu Asp Pro Ala Met

85 90 95

Trp

<210> 6

<211> 224

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 6

Met Glu Lys Leu Leu Cys Phe Leu Val Leu Thr Ser Leu Ser His Ala

1 5 10 15

Phe Gly Gln Thr Asp Met Ser Arg Lys Ala Phe Val Phe Pro Lys Glu

20 25 30

Ser Asp Thr Ser Tyr Val Ser Leu Lys Ala Pro Leu Thr Lys Pro Leu

35 40 45

Lys Ala Phe Thr Val Cys Leu His Phe Tyr Thr Glu Leu Ser Ser Thr

50 55 60

Arg Gly Tyr Ser Ile Phe Ser Tyr Ala Thr Lys Arg Gln Asp Asn Glu

65 70 75 80

Ile Leu Ile Phe Trp Ser Lys Asp Ile Gly Tyr Ser Phe Thr Val Gly

85 90 95

Gly Ser Glu Ile Leu Phe Glu Val Pro Glu Val Thr Val Ala Pro Val

100 105 110

His Ile Cys Thr Ser Trp Glu Ser Ala Ser Gly Ile Val Glu Phe Trp

115 120 125

Val Asp Gly Lys Pro Arg Val Arg Lys Ser Leu Lys Lys Gly Tyr Thr

130 135 140

Val Gly Ala Glu Ala Ser Ile Ile Leu Gly Gln Glu Gln Asp Ser Phe

145 150 155 160

Gly Gly Asn Phe Glu Gly Ser Gln Ser Leu Val Gly Asp Ile Gly Asn

165 170 175

Val Asn Met Trp Asp Phe Val Leu Ser Pro Asp Glu Ile Asn Thr Ile

180 185 190

Tyr Leu Gly Gly Pro Phe Ser Pro Asn Val Leu Asn Trp Arg Ala Leu

195 200 205

Lys Tyr Glu Val Gln Gly Glu Val Phe Thr Lys Pro Gln Leu Trp Pro

210 215 220

<210> 7

<211> 707

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 7

Met Ser Leu Trp Gln Pro Leu Val Leu Val Leu Leu Val Leu Gly Cys

1 5 10 15

Cys Phe Ala Ala Pro Arg Gln Arg Gln Ser Thr Leu Val Leu Phe Pro

20 25 30

Gly Asp Leu Arg Thr Asn Leu Thr Asp Arg Gln Leu Ala Glu Glu Tyr

35 40 45

Leu Tyr Arg Tyr Gly Tyr Thr Arg Val Ala Glu Met Arg Gly Glu Ser

50 55 60

Lys Ser Leu Gly Pro Ala Leu Leu Leu Leu Gln Lys Gln Leu Ser Leu

65 70 75 80

Pro Glu Thr Gly Glu Leu Asp Ser Ala Thr Leu Lys Ala Met Arg Thr

85 90 95

Pro Arg Cys Gly Val Pro Asp Leu Gly Arg Phe Gln Thr Phe Glu Gly

100 105 110

Asp Leu Lys Trp His His His Asn Ile Thr Tyr Trp Ile Gln Asn Tyr

115 120 125

Ser Glu Asp Leu Pro Arg Ala Val Ile Asp Asp Ala Phe Ala Arg Ala

130 135 140

Phe Ala Leu Trp Ser Ala Val Thr Pro Leu Thr Phe Thr Arg Val Tyr

145 150 155 160

Ser Arg Asp Ala Asp Ile Val Ile Gln Phe Gly Val Ala Glu His Gly

165 170 175

Asp Gly Tyr Pro Phe Asp Gly Lys Asp Gly Leu Leu Ala His Ala Phe

180 185 190

Pro Pro Gly Pro Gly Ile Gln Gly Asp Ala His Phe Asp Asp Asp Glu

195 200 205

Leu Trp Ser Leu Gly Lys Gly Val Val Val Pro Thr Arg Phe Gly Asn

210 215 220

Ala Asp Gly Ala Ala Cys His Phe Pro Phe Ile Phe Glu Gly Arg Ser

225 230 235 240

Tyr Ser Ala Cys Thr Thr Asp Gly Arg Ser Asp Gly Leu Pro Trp Cys

245 250 255

Ser Thr Thr Ala Asn Tyr Asp Thr Asp Asp Arg Phe Gly Phe Cys Pro

260 265 270

Ser Glu Arg Leu Tyr Thr Arg Asp Gly Asn Ala Asp Gly Lys Pro Cys

275 280 285

Gln Phe Pro Phe Ile Phe Gln Gly Gln Ser Tyr Ser Ala Cys Thr Thr

290 295 300

Asp Gly Arg Ser Asp Gly Tyr Arg Trp Cys Ala Thr Thr Ala Asn Tyr

305 310 315 320

Asp Arg Asp Lys Leu Phe Gly Phe Cys Pro Thr Arg Ala Asp Ser Thr

325 330 335

Val Met Gly Gly Asn Ser Ala Gly Glu Leu Cys Val Phe Pro Phe Thr

340 345 350

Phe Leu Gly Lys Glu Tyr Ser Thr Cys Thr Ser Glu Gly Arg Gly Asp

355 360 365

Gly Arg Leu Trp Cys Ala Thr Thr Ser Asn Phe Asp Ser Asp Lys Lys

370 375 380

Trp Gly Phe Cys Pro Asp Gln Gly Tyr Ser Leu Phe Leu Val Ala Ala

385 390 395 400

His Glu Phe Gly His Ala Leu Gly Leu Asp His Ser Ser Val Pro Glu

405 410 415

Ala Leu Met Tyr Pro Met Tyr Arg Phe Thr Glu Gly Pro Pro Leu His

420 425 430

Lys Asp Asp Val Asn Gly Ile Arg His Leu Tyr Gly Pro Arg Pro Glu

435 440 445

Pro Glu Pro Arg Pro Pro Thr Thr Thr Thr Pro Gln Pro Thr Ala Pro

450 455 460

Pro Thr Val Cys Pro Thr Gly Pro Pro Thr Val His Pro Ser Glu Arg

465 470 475 480

Pro Thr Ala Gly Pro Thr Gly Pro Pro Ser Ala Gly Pro Thr Gly Pro

485 490 495

Pro Thr Ala Gly Pro Ser Thr Ala Thr Thr Val Pro Leu Ser Pro Val

500 505 510

Asp Asp Ala Cys Asn Val Asn Ile Phe Asp Ala Ile Ala Glu Ile Gly

515 520 525

Asn Gln Leu Tyr Leu Phe Lys Asp Gly Lys Tyr Trp Arg Phe Ser Glu

530 535 540

Gly Arg Gly Ser Arg Pro Gln Gly Pro Phe Leu Ile Ala Asp Lys Trp

545 550 555 560

Pro Ala Leu Pro Arg Lys Leu Asp Ser Val Phe Glu Glu Pro Leu Ser

565 570 575

Lys Lys Leu Phe Phe Phe Ser Gly Arg Gln Val Trp Val Tyr Thr Gly

580 585 590

Ala Ser Val Leu Gly Pro Arg Arg Leu Asp Lys Leu Gly Leu Gly Ala

595 600 605

Asp Val Ala Gln Val Thr Gly Ala Leu Arg Ser Gly Arg Gly Lys Met

610 615 620

Leu Leu Phe Ser Gly Arg Arg Leu Trp Arg Phe Asp Val Lys Ala Gln

625 630 635 640

Met Val Asp Pro Arg Ser Ala Ser Glu Val Asp Arg Met Phe Pro Gly

645 650 655

Val Pro Leu Asp Thr His Asp Val Phe Gln Tyr Arg Glu Lys Ala Tyr

660 665 670

Phe Cys Gln Asp Arg Phe Tyr Trp Arg Val Ser Ser Arg Ser Glu Leu

675 680 685

Asn Gln Val Asp Gln Val Gly Tyr Val Thr Tyr Asp Ile Leu Gln Cys

690 695 700

Pro Glu Asp

705

<210> 8

<211> 275

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 8

Met Ser Ser Phe Gly Tyr Arg Thr Leu Thr Val Ala Leu Phe Thr Leu

1 5 10 15

Ile Cys Cys Pro Gly Ser Asp Glu Lys Val Phe Glu Val His Val Arg

20 25 30

Pro Lys Lys Leu Ala Val Glu Pro Lys Gly Ser Leu Glu Val Asn Cys

35 40 45

Ser Thr Thr Cys Asn Gln Pro Glu Val Gly Gly Leu Glu Thr Ser Leu

50 55 60

Asp Lys Ile Leu Leu Asp Glu Gln Ala Gln Trp Lys His Tyr Leu Val

65 70 75 80

Ser Asn Ile Ser His Asp Thr Val Leu Gln Cys His Phe Thr Cys Ser

85 90 95

Gly Lys Gln Glu Ser Met Asn Ser Asn Val Ser Val Tyr Gln Pro Pro

100 105 110

Arg Gln Val Ile Leu Thr Leu Gln Pro Thr Leu Val Ala Val Gly Lys

115 120 125

Ser Phe Thr Ile Glu Cys Arg Val Pro Thr Val Glu Pro Leu Asp Ser

130 135 140

Leu Thr Leu Phe Leu Phe Arg Gly Asn Glu Thr Leu His Tyr Glu Thr

145 150 155 160

Phe Gly Lys Ala Ala Pro Ala Pro Gln Glu Ala Thr Ala Thr Phe Asn

165 170 175

Ser Thr Ala Asp Arg Glu Asp Gly His Arg Asn Phe Ser Cys Leu Ala

180 185 190

Val Leu Asp Leu Met Ser Arg Gly Gly Asn Ile Phe His Lys His Ser

195 200 205

Ala Pro Lys Met Leu Glu Ile Tyr Glu Pro Val Ser Asp Ser Gln Met

210 215 220

Val Ile Ile Val Thr Val Val Ser Val Leu Leu Ser Leu Phe Val Thr

225 230 235 240

Ser Val Leu Leu Cys Phe Ile Phe Gly Gln His Leu Arg Gln Gln Arg

245 250 255

Met Gly Thr Tyr Gly Val Arg Ala Ala Trp Arg Arg Leu Pro Gln Ala

260 265 270

Phe Arg Pro

275

Claims

1. A serum molecular diagnostic marker for mild traumatic brain injury, characterized in that it comprises one or more of NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9 or ICAM-2.

2. the serum molecular diagnostic marker of light traumatic brain injury according to claim 1, is characterized in that, the aminoacid sequence of NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9 and ICAM-2 is as SEQ ID NO.1-SEQ ID NO.8 are shown.

3. The application of the serum molecular diagnostic marker for mild traumatic brain injury according to claim 1 in the preparation of a diagnostic product for mild traumatic brain injury.

4. The application according to claim 3, wherein the diagnostic product comprises a reagent for detecting the one or more markers by detecting the one or more markers in the serum of the subject The concentration of the marker is used to judge whether the subject suffers from mild traumatic brain injury.

5 . The application according to claim 3 , wherein the reagent is a reagent required for detecting the concentration of the one or more markers based on gene chip detection or PCR. 6 .

6. The application according to claim 3, wherein one or more of the markers NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9, ICAM-2 are present in the Compared with the non-minor brain injury tissue, the expression in the mild brain injury tissue was significantly higher.

7. The application according to any one of claims 3-6, wherein the diagnostic product is a kit, a chip or a detection platform.

8. A light traumatic brain injury diagnostic kit, characterized in that, the test kit is used to detect NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9, ICAM-2 in light brain trauma one or more of them.

9. test kit according to claim 7, is characterized in that, this test kit comprises the specific antibody of eight kinds of proteins of NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9 and ICAM-2 .

10. A protein chip for the diagnosis of light traumatic brain injury comprising a solid phase carrier and the specificity of eight proteins of NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9 and ICAM-2 immobilized on the solid phase carrier Antibody.